Identifing the markers for chemotherapy - induced liver damage
Not Applicable
- Conditions
- iver tumors
- Registration Number
- JPRN-UMIN000008602
- Lead Sponsor
- Yokohama City University, Department of Gastroenterological Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
none
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation between preoperative fibroscan data or melcaptal/nonmercaptal albumin and pathological liver damage
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie chemotherapy-induced liver injury in hepatocellular carcinoma patients?
How does JPRN-UMIN000008602 compare to standard-of-care monitoring for cisplatin-related hepatotoxicity in liver tumor patients?
Which serum biomarkers predict chemotherapy-induced liver damage in patients with metastatic liver tumors?
What are the management strategies for doxorubicin-induced hepatotoxicity in Yokohama City University's liver tumor trial?
How do combination therapies like sorafenib and lenvatinib affect liver damage markers in hepatocellular carcinoma?